Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kamada Ltd. (KMDA : NSDQ)

• Company Description    Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. Number of Employees: 357

• Price / Volume Information    Yesterday's Closing Price: $4.75 Daily Weekly Monthly 20 Day Moving Average: 13,303 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.99 52 Week High: $6.96 52 Week Low: $4.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.41% -6.22% 12 Week -19.35% -12.50% Year To Date -27.81% -14.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HOLTZMAN ST. SCIENCE PARK - REHOVOT,L3 7670402 ISR ph: 972-8940-6472 fax: 972-8940-6473 ir@kamada.com http://www.kamada.com

• General Corporate Information    Officers Amir London - Chief Executive Officer Lilach Asher Topilsky - Chairman of the Board Eran Nir - Chief Operating Officer Chaime Orlev - Chief Financial Officer Amiram Boehm - Director Peer Information Kamada Ltd. (CORR.) Kamada Ltd. (RSPI) Kamada Ltd. (CGXP) Kamada Ltd. (BGEN) Kamada Ltd. (GTBP) Kamada Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M6240T109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/21 Next Expected EPS Date: 05/17/22 Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 0.99 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/17/22

• Fundamental Ratios P/E Current FY Estimate: 33.93 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.20 Price/Cash Flow: 44.25 Price / Sales: - EPS Growth vs. Year Ago Period: -350.00% vs. Previous Quarter: -400.00% Sales Growth vs. Year Ago Period: -0.23% vs. Previous Quarter: 36.62% ROE 03/31/22 - - 12/31/21 - -0.91 09/30/21 - 2.44 ROA 03/31/22 - - 12/31/21 - -0.68 09/30/21 - 2.06 Current Ratio 03/31/22 - - 12/31/21 - 2.41 09/30/21 - 6.73 Quick Ratio 03/31/22 - - 12/31/21 - 1.16 09/30/21 - 4.92 Operating Margin 03/31/22 - - 12/31/21 - -1.59 09/30/21 - 4.25 Net Margin 03/31/22 - - 12/31/21 - -2.15 09/30/21 - 4.25 Pre-Tax Margin 03/31/22 - - 12/31/21 - -1.82 09/30/21 - 4.52 Book Value 03/31/22 - - 12/31/21 - 3.97 09/30/21 - 4.08 Inventory Turnover 03/31/22 - - 12/31/21 - 1.46 09/30/21 - 1.59 Debt-to-Equity 03/31/22 - - 12/31/21 - 0.10 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 8.96 09/30/21 - 0.00

Powered by Zacks Investment Research ©